Immune response to COVID-19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy
Description
Patients with Waldenström macroglobulinaemia (WM) are at increased risk of severe COVID-19 infection and have poor immune responses to COVID-19 vaccination. This study assessed whether a closely monitored pause in Bruton's Tyrosine Kinase inhibitor
